Matinas BioPharma shares pop on patent approval for MAT9001

The clinical-stage biopharmaceutical group Matinas BioPharma Holdings (NYSEAMERICAN:MTNB) is on the receiving end of good news from the US Patent and Trademark Office which has issued a patent to protect MAT9001, its prescription-only omega 3 fatty acid.

The patent covers methods of use for its omega-3 fatty acid therapy, which is in development for the treatment of heart and metabolic conditions such as high cholesterol.  The patent will last through 2033.

Investors sent Matinas shares up 8% to $0.85 in response to the announcement.

“Recent developments in the cardiovascular space have placed renewed focus on MAT9001, our proprietary and purposefully designed omega-3 product,” noted Matinas CEO Jerome Jabbour in a statement.

“Over the past few years, we continued to be diligent in the prosecution of important intellectual property covering our MAT9001 product and the ongoing expansion of our intellectual property portfolio is an integral aspect of our development strategy,” he added.

READ: Maxim Group sees upside in Matinas BioPharma’s inventive lipid nanocrystal technology

MAT 9001 is made up of docosapentaenoic acid (DPA), a potent but less prevalent omega-3 fatty acid, and other omega-3 fatty acids. Its new patent is entitled “Omega-3 pentaenoic acid compositions and methods of use.”

Based in Bedminster, New Jersey, Matinas focuses on the development of medicines using its lipid nano-crystal platform delivery technology. The company’s innovative technology utilizes lipid nano-crystals which can encapsulate small molecule drugs, oligonucleotides, vaccines, peptides, proteins and other medicines and potentially make them safer and more tolerable.

Contact Ellen Kelleher at [email protected]

Story by ProactiveInvestors